The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Differential effects of partial and complete loss of TREM2 on microglial injury response and tauopathy
Open accessAbstract
Alzheimer’s disease (AD), the most common form of dementia, is characterized by the abnormal accumulation of amyloid plaques and hyperphosphorylated tau aggregates, as well as microgliosis. Hemizygous missense variants in Triggering Receptor Expressed on Myeloid Cells 2 ( TREM2 ) are associated with elevated risk for developing late-onset AD. These variants are hypothesized to result in loss of function, mimicking TREM2 haploinsufficiency. However, the consequences of TREM2 haploinsufficiency on tau pathology and microglial function remain unknown. We report the effects of partial and complete loss of TREM2 on microglial function and tau-associated deficits. In vivo imaging revealed that microglia from aged TREM2-haploinsufficient mice show a greater impairment in their injury response compared with microglia from aged TREM2-KO mice. In transgenic mice expressing mutant human tau, TREM2 haploinsufficiency, but not complete loss of TREM2, increased tau pathology. In addition, whereas complete TREM2 deficiency protected against tau-mediated microglial activation and atrophy, TREM2 haploinsufficiency elevated expression of proinflammatory markers and exacerbated atrophy at a late stage of disease. The differential effects of partial and complete loss of TREM2 on microglial function and tau pathology provide important insights into the critical role of TREM2 in AD pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent important studies have also shown that impaired/absent Trem2 function attenuates the microglial response to amyloid pathology by regulating microglial number around plaques, regulating microglial activity, and restricting neuritic damage (37,61,84–87,95–99).”
From Trem2 promotes anti-inflammatory responses in microglia and is suppressed under pro-inflammatory conditions (2020) · cites this paper as [97]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“a complete deficiency in TREM2 protected PS19 mice against tau-mediated microgliosis and brain atrophy [18].”
From TREM2-Deficient Microglia Attenuate Tau Spreading In Vivo (2023) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TREM2 haploinsufficiency (50% reduction in TREM2 levels) increased tau pathology [18].”
From TREM2-Deficient Microglia Attenuate Tau Spreading In Vivo (2023) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, manipulation of expression of Trem2, Tyrobp, Cx3cl1/Cx3cr1, IL1β, and IFN-γ have all been shown to have opposing effects on amyloid and tau pathologies [49–51, 55–65].”
From Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways (2022) · cites this paper as [49]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“More recently, this dichotomy has been elegantly demonstrated in multiple models of Trem2 and Tyrobp [49–51, 55–59].”
From Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways (2022) · cites this paper as [49]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Deficiency of Apoe or Trem2 attenuates tau-dependent neuroinflammation and neurodegeneration in mice expressing human P301S mutant tau (PS19 mice) (Shi et al., 2017; Leyns et al., 2017; Sayed et al., 2018).”
From Cholesterol 25-hydroxylase mediates neuroinflammation and neurodegeneration in a mouse model of tauopathy (2024) · cites this paper as Sayed et al., 2018
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Further complicating matters, haploinsufficiency and total deficiency of TREM2 can lead to opposite effects,44”
From Microglial INPP5D limits plaque formation and glial reactivity in the PSAPP mouse model of Alzheimer's disease (2023) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“In another study that evaluated the effect of TREM2 loss-of-function in the PS19 model, a 50% decrease in TREM2 but not a total reduction enhanced tau phosphorylation and aggregation [18].”
From TREM2-Deficient Microglia Attenuate Tau Spreading In Vivo (2023) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Surprisingly, recent studies have identified a role for gene dosage in microglial genes, including TREM2, whereby partial and complete loss of gene expression resulted in divergent phenotypic consequences, emphasizing the importance of exploring total PLCG2 loss.”
From PLCG2 modulates TREM2 expression and signaling in response to Alzheimer's disease pathology (2025) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo
Nimmerjahn, A., Kirchhoff, F., & Helmchen, F. (2005) · Science · doi:10.1126/science.1110647 · Cited by 5,827
Zhang, Y., Chen, K., Sloan, S. A., Bennett, M. L., Scholze, A. R., O'Keeffe, S., Phatnani, H. P., Guarnieri, P., Caneda, C., Ruderisch, N., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1860-14.2014 · Cited by 4,875
ATP mediates rapid microglial response to local brain injury in vivo
Davalos, D., Grutzendler, J., Yang, G., Kim, J. V., Zuo, Y., Jung, S., Littman, D. R., Dustin, M. L., & Gan, W.-B. (2005) · Nature Neuroscience · doi:10.1038/nn1472 · Cited by 3,913
Self-citationTREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Jung, S., Aliberti, J., Graemmel, P., Sunshine, M. J., Kreutzberg, G. W., Sher, A., & Littman, D. R. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.11.4106-4114.2000 · Cited by 2,632
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558
Identification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model
Wang, Y., Cella, M., Mallinson, K., Ulrich, J. D., Young, K. L., Robinette, M. L., Gilfillan, S., Krishnan, G. M., Sudhakar, S., Zinselmeyer, B. H., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.049 · Cited by 1,736
Depletion of microglia and inhibition of exosome synthesis halt tau propagation
Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., & Ikezu, T. (2015) · Nature Neuroscience · doi:10.1038/nn.4132 · Cited by 1,591
Cited by
Sorted by citations
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
“In the PS19 tauopathy mouse, TREM2 deletion significantly reduced tau-mediated neurodegeneration and astrogliosis (Leyns et al., 2017; Sayed et al., 2018).”
Role of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
“178,179 Notably, the impact of TREM2 on A β and tau pathology may vary at different disease stages.”
BackgroundTREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge
Nugent, A. A., Lin, K., van Lengerich, B., Lianoglou, S., Przybyla, L., Davis, S. S., Llapashtica, C., Wang, J., Kim, D. J., Xia, D., et al. (2020) · Neuron · doi:10.1016/j.neuron.2019.12.007 · Cited by 745
New insights into the role of TREM2 in Alzheimer’s disease
Gratuze, M., Leyns, C. E. G., & Holtzman, D. M. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0298-9 · Cited by 489
Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy
Zheng, Q., & Wang, X. (2024) · Protein & Cell · doi:10.1093/procel/pwae026 · Cited by 483
The complexity of tau in Alzheimer’s disease
Naseri, N. N., Wang, H., Guo, J. D., Sharma, M., & Luo, W. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.04.022 · Cited by 393
Immune Signaling in Neurodegeneration
Hammond, T. R., Marsh, S. E., & Stevens, B. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.016 · Cited by 336
“However, they found that haploinsufficiency, which the authors argued better mimics a partial loss of function, increased tau pathology (Sayed et al., 2018).”
BackgroundTREM2 function impedes tau seeding in neuritic plaques
Leyns, C. E. G., Gratuze, M., Narasimhan, S., Jain, N., Koscal, L. J., Jiang, H., Manis, M., Colonna, M., Lee, V. M. Y., Ulrich, J. D., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0433-0 · Cited by 332
Ewers, M., Franzmeier, N., Suárez-Calvet, M., Morenas-Rodriguez, E., Caballero, M. A. A., Kleinberger, G., Piccio, L., Cruchaga, C., Deming, Y., Dichgans, M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav6221 · Cited by 327
“In addition, a recent study reported that selective TREM2 haploin-sufficiency but not a complete loss of TREM2 increased tau pathology, which may suggest that some compensatory mechanisms occurred after the complete loss of TREM2 function ( 52 ).”
Emerging roles of innate and adaptive immunity in Alzheimer’s disease
Chen, X., & Holtzman, D. M. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.016 · Cited by 297
Trem2 restrains the enhancement of tau accumulation and neurodegeneration by β-amyloid pathology
Lee, S.-H., Meilandt, W. J., Xie, L., Gandham, V. D., Ngu, H., Barck, K. H., Rezzonico, M. G., Imperio, J., Lalehzadeh, G., Huntley, M. A., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.02.010 · Cited by 300
Impact of TREM2R47H variant on tau pathology–induced gliosis and neurodegeneration
Gratuze, M., Leyns, C. E. G., Sauerbeck, A. D., St-Pierre, M.-K., Xiong, M., Kim, N., Serrano, J. R., Tremblay, M.-È., Kummer, T. T., Colonna, M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138179 · Cited by 252
“previously reported that complete loss of TREM2 protects against tau-mediated brain atrophy as well as lower microgliosis (25, 26).”
BackgroundLiu, W., Taso, O., Wang, R., Bayram, S., Graham, A. C., Garcia-Reitboeck, P., Mallach, A., Andrews, W. D., Piers, T. M., Botia, J. A., et al. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa209 · Cited by 214
TREM2, microglia, and Alzheimer’s disease.
Qin, Q., Teng, Z., Liu, C., Li, Q., Yin, Y., & Tang, Y. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111438 · Cited by 219
Intersection of pathological tau and microglia at the synapse
Vogels, T., Murgoci, A.-N., & Hromádka, T. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0754-y · Cited by 197
“Indeed, haploinsufficiency of AD risk gene TREM2 only leads to impaired response of microglia to injury in old mice [261].”
BackgroundTREM2 dependent and independent functions of microglia in Alzheimer’s disease
Hou, J., Chen, Y., Grajales-Reyes, G., & Colonna, M. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00588-y · Cited by 191
“observed that TREM2 deficiency prevented microglial activation and hippocampal atrophy in 9-month-old PS19 mouse, while Trem2+/- mice showed exacerbated tau pathology [161].”
BackgroundUpdates on mouse models of Alzheimer’s disease
Zhong, M. Z., Peng, T., Duarte, M. L., Wang, M., & Cai, D. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00712-0 · Cited by 189
“We curated total 11 publicly available transcriptomic data including datasets generated from microglia derived from AD mouse brains as well as datasets from bulk brain tissue of various AD mouse models (Table 3) [99, 133, 170–174].”
MethodZhong, L., Sheng, X., Wang, W., Li, Y., Zhuo, R., Wang, K., Zhang, L., Hu, D.-D., Hong, Y., Chen, L., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.016 · Cited by 168
Self-citationAD-linked R47H- TREM2 mutation induces disease-enhancing microglial states via AKT hyperactivation
Sayed, F. A., Kodama, L., Fan, L., Carling, G. K., Udeochu, J. C., Le, D., Li, Q., Zhou, L., Wong, M. Y., Horowitz, R., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe3947 · Cited by 155
Self-citationMicroglial priming of antigen presentation and adaptive stimulation in Alzheimer’s disease
Das, R., & Chinnathambi, S. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03132-2 · Cited by 147
Fang, K., Li, H., Chen, X.-X., Gao, X., Huang, L.-L., Du, A.-Q., Jiang, C., Li, H., & Ge, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01544 · Cited by 136
Long, H., Simmons, A., Mayorga, A. J., Burgess, B., Nguyen, T., Budda, B., Rychkova, A., Rhinn, H., Tassi, I., Ward, M. E., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01599-1 · Cited by 153
“Conflicting results on the effect of TREM2 deficiency on tau pathology have been reported in pure tauopathy models [33–36] as well as in combined models of Aβ and tau pathologies.”
BackgroundTransgenic Mouse Models of Alzheimer’s Disease: An Integrative Analysis
Sanchez-Varo, R. M., Mejias‐Ortega, M., Fernandez-Valenzuela, J. J., Nuñez‐Diaz, C., Cáceres-Palomo, L., Vegas‐Gomez, L., Sánchez‐Mejías, E., Trujillo‐Estrada, L., García‐León, J. A., Moreno‐González, I., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105404 · Cited by 136
Trem2 deletion enhances tau dispersion and pathology through microglia exosomes
Zhu, B., Liu, Y., Hwang, S., Archuleta, K., Huang, H., Campos, A., Murad, R., Piña-Crespo, J., Xu, H., & Huang, T. Y. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00562-8 · Cited by 127
“(B) Wildtype (WT) mice were injected with AAV‑GFP and AAV‑tau in combination (1 × 109 AAV particles each), and GFP (green), AT8 (pS202, T305 tau, red) and DAPI (nuclei, blue) staining within the MEC and hippocampal dentate gyrus (DG) was imaged by confocal microscopy 5 weeks following injection.”
BackgroundInfluentialTREM2: Potential therapeutic targeting of microglia for Alzheimer's disease
Li, Y., Xu, H., Wang, H., Yang, K., Luan, J., & Wang, S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115218 · Cited by 133
Leveraging preclinical models for the development of Alzheimer disease therapeutics
Scearce-Levie, K. A., Sanchez, P. E., & Lewcock, J. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0065-9 · Cited by 121
Dong, Y., Yu, H., Li, X., Bian, K., Zheng, Y., Dai, M., Feng, X., Sun, Y., He, Y. T., Yu, B., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02567-y · Cited by 127
“In the TauP301S tauopathy mouse model, microglial inactivation attenuates neuroinflammation and tau-mediated neurodegeneration, indicating that microglia contribute to neuronal death in models of tau-mediated neurodegeneration [22, 23].”
BackgroundProkop, S., Miller, K. R., Labra, S. R., Pitkin, R. M., Hoxha, K., Narasimhan, S., Changolkar, L., Rosenbloom, A., Lee, V. M.-Y., & Trojanowski, J. Q. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02048-2 · Cited by 119
Pagán, F., Hebron, M. L., Wilmarth, B., Torres-Yaghi, Y. A., Lawler, A., Mundel, E. E., Yusuf, N., Starr, N. J., Arellano, J., Howard, H. H., et al. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.470 · Cited by 121
TREM2 ectodomain and its soluble form in Alzheimer’s disease
Yang, J., Fu, Z., Zhang, X., Xiong, M., Meng, L., & Zhang, Z. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01878-2 · Cited by 113
“TREM2 deletion protected against atrophy and reduced inflammatory responses in P301S mice [99].”
BackgroundA cell therapy approach to restore microglial Trem2 function in a mouse model of Alzheimer’s disease
Yoo, Y., Neumayer, G., Shibuya, Y., Mader, M. M.-D., & Wernig, M. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.07.006 · Cited by 109
Distinct Signaling Pathways Regulate TREM2 Phagocytic and NFκB Antagonistic Activities
Yao, H., Coppola, K., Schweig, J. E., Crawford, F., Mullan, M., & Paris, D. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00457 · Cited by 110
TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4.
Gratuze, M., Schlachetzki, J. C. M., D’Oliveira Albanus, R., Jain, N., Novotny, B., Brase, L., Rodriguez, L., Mansel, C., Kipnis, M., O’Brien, S., et al. (2023) · Neuron · doi:10.1016/j.neuron.2022.10.022 · Cited by 115
Role of Microglial Cells in Alzheimer’s Disease Tau Propagation
Španić, E., Horvat, L. L., Hof, P. R., & Šimić, G. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00271 · Cited by 112
Jiang, S., Maphis, N. M., Binder, J., Chisholm, D., Weston, L., Duran, W., Peterson, C., Zimmerman, A., Mandell, M. A., Jett, S. D., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109720 · Cited by 92
“…made by few previous reports on the colocalization of NLRP3, IL-1 β , and caspase-1 with pTau in the human AD brains (Ahmed et al., 2017) and significantly elevated levels of proinflammatory cytokines TNF-α , IL-1 α , and IL-1 β in the P301S mouse model of tauopathy (Sayed et al., 2018).”
TREM2 in Alzheimer’s Disease: Microglial Survival and Energy Metabolism
Zheng, H., Cheng, B., Li, Y., Li, X., Chen, X., & Zhang, Y.-W. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00395 · Cited by 94
“…Aβ pathology (Wang et al., 2016; Lee et al., 2018), hyperphosphorylation and aggregation of tau (Bemiller et al., 2017; Leyns and Holtzman, 2017; Sayed et al., 2018), microgliosis and inflammation in AD (Zhong et al., 2015, 2017b; Zheng et al., 2016; Jay et al., 2017a; Ulrich et al., 2017).”
BackgroundTauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies
Silva, M. C., & Haggarty, S. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238948 · Cited by 89
Carling, G. K., Fan, L., Foxe, N. R., Norman, K., Wong, M. Y., Zhu, D., Corona, C., Razzoli, A., Yu, F., Yarahmady, A., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.09.006 · Cited by 89
Senescent Microglia: The Key to the Ageing Brain?
Greenwood, E. K., & Brown, D. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094402 · Cited by 84
“TREM2 knockout or dysfunction has been linked to a shift towards glycolytic metabolism and away from the more efficient oxidative phosphorylation [69,156,157].”
BackgroundBenítez, D. P., Jiang, S., Wood, J. I., Wang, R., Hall, C. M., Peerboom, C., Wong, N. S. M., Stringer, K. M., Vitanova, K. S., Smith, V. C., et al. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00457-0 · Cited by 81
“Conversely, complete Trem2 deficiency is protective in the tau mice [59].”
BackgroundMicroglia and Wnt Pathways: Prospects for Inflammation in Alzheimer’s Disease
Yang, Y., & Zhang, Z. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00110 · Cited by 76
Lee, S.-H., Rezzonico, M. G., Friedman, B. A., Huntley, M. H., Meilandt, W. J., Pandey, S., Chen, Y.-J. J., Easton, A. E., Modrusan, Z. D., Hansen, D. V., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110158 · Cited by 82
Acute Trem2 reduction triggers increased microglial phagocytosis, slowing amyloid deposition in mice
Schoch, K. M., Ezerskiy, L. A., Morhaus, M. M., Bannon, R. N., Sauerbeck, A. D., Shabsovich, M., Jafar-nejad, P., Rigo, F., & Miller, T. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2100356118 · Cited by 78
“However, TREM2 function and microglial activation also may depend on other factors, such as age (20–22), disease insult or injury (23–25), gene dosage (26), and the presence of Aβ and/or tau pathology (19, 27–29), which together reveal specific contexts”
BackgroundCastranio, E. L., Hasel, P., Haure‐Mirande, J., Ramirez Jimenez, A. V., Hamilton, B. W., Kim, R. D., Glabe, C. G., Wang, M., Zhang, B., Gandy, S., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12821 · Cited by 74
“Further complicating matters, haploinsufficiency and total deficiency of TREM2 can lead to opposite effects, 44 and differing outcomes have also been reported with microglial depletion.”
Loss of TREM2 Confers Resilience to Synaptic and Cognitive Impairment in Aged Mice
Qu, W., & Li, L. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.2193-20.2020 · Cited by 71
“…tau pathology and seeding but decreased tau-mediated neurodegeneration, whereas TREM2 haplodeficiency aggravates neuroinflammation and exacerbates tau pathology and brain atrophy, showing a complex role of TREM2 in the pathogenic process of AD (Leyns et al., 2017, 2019; Sayed et al., 2018).”
BackgroundTREM2 and sTREM2 in Alzheimer’s disease: from mechanisms to therapies
Zhang, L., Xiang, X., Li, Y., Bu, G., & Chen, X. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00834-z · Cited by 87
“However, heterozygous TREM2 deficiency shows the opposite effect, intensifying tau pathology, brain atrophy, and pro-inflammatory responses in the same model [103].”
Fang, K., Li, H., Chen, X.-X., Gao, X., Huang, L.-L., Du, A.-Q., Jiang, C., Li, H., & Ge, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00518 · Cited by 72
Microglia, Trem2, and Neurodegeneration
Shi, Q., Gutierrez, R. A., & Bhat, M. A. (2025) · The Neuroscientist · doi:10.1177/10738584241254118 · Cited by 69
“However, the roles for Trem2 in pure tauopathy mouse models appear to be more complex and somewhat contradictory (Bemiller and others 2017; Sayed and others 2018).”
Microglia: Friend and foe in tauopathy
Odfalk, K. F., Bieniek, K. F., & Hopp, S. C. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102306 · Cited by 60
Audrain, M., Haure‐Mirande, J., Mleczko, J., Wang, M., Griffin, J. K., St George‐Hyslop, P. H., Fraser, P., Zhang, B., Gandy, S., & Ehrlich, M. E. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12256 · Cited by 65
Delizannis, A. T., Nonneman, A., Tsering, W., Bondt, A. D., den Wyngaert, I. V., Zhang, B., Meymand, E. S., Olufemi, M. F., Koivula, P. P., Maimaiti, S., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01251-1 · Cited by 71
“A somewhat similar trend was previously observed, where TREM2 haploinsufficiency was found to be more detrimental than TREM2 KO in the development of tau pathology in a mouse model with mutant tau over-expression [35].”
ResultRole of TREM2 in Alzheimer’s Disease: A Long Road Ahead
Kulkarni, B., Kumar, D., Martins, N. A., & Sellamuthu, S. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02477-9 · Cited by 53
Codocedo, J. F., Mera-Reina, C., Bor-Chian Lin, P., Fallen, P. B., Puntambekar, S. S., Casali, B. T., Jury-Garfe, N., Martinez, P., Lasagna-Reeves, C. A., & Landreth, G. E. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114488 · Cited by 52
“58 Moreover, PLCG2, another important AD risk gene, can regulate divergent microglial functions via Trem2 or TLR association, 59 reinforcing the idea that many molecular players can drive microglial phenotypes depending not only on its enzymatic activity but also on its cellular localization and…”
The role of microglia in Alzheimer's disease and progress of treatment
Guan, Y., Zhang, L., Wang, S., Deng, Y., Zhou, H., Chen, D., & Zhang, L. (2022) · Ibrain · doi:10.1002/ibra.12023 · Cited by 52
“9 Our aim is to better elucidate the mediating role of microglia in the treat-ment of AD by exploring the mechanism of microglia in AD, and to summarize relevant targets and drugs.”
Tran, K. M., Kawauchi, S., Kramár, E. A., Rezaie, N., Liang, H. Y., Sakr, J., Gómez-Arboledas, Á., Arreola, M. A., da Cunha, C., Phan, J., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00598-4 · Cited by 55
“Crossing of these mice with the PS19 mouse model of tauopathy found that the R47H variant exacerbates damage and inflammation and does not function as a loss of function variant [18], unlike similar crosses of PS19 mice with the human BAC TREM2R47H model which actually protected against microglia activation and subseq…”
You, J., Youssef, M., Santos, J. R., Lee, J., & Park, J. (2023) · Biology · doi:10.3390/biology12101307 · Cited by 60
The role of TREM2 in Alzheimer’s disease: from the perspective of Tau
Huang, W., Huang, J., Huang, N., & Luo, Y. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1280257 · Cited by 49
Penney, J., Ralvenius, W. T., Loon, A., Cerit, O., Dileep, V., Milo, B., Pao, P., Woolf, H., & Tsai, L. (2024) · Glia · doi:10.1002/glia.24485 · Cited by 52
“Impaired microglial responses to laser-induced injury have been reported in the brains of TREM2 heterozygous and homozygous KO mice (Mazaheri et al., 2017; Sayed et al., 2018).”
BackgroundToral-Rios, D., Long, J. M., Ulrich, J. D., Yu, J., Strickland, M. R., Han, X., Holtzman, D. M., Cashikar, A. G., & Paul, S. M. (2024) · Journal of Experimental Medicine · doi:10.1084/jem.20232000 · Cited by 47
Gao, X.-R., Chen, Z., Fang, K., Xu, J.-X., & Ge, J.-F. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01590-x · Cited by 47
Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders
Golde, T. E. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.027 · Cited by 45
Neuronal ApoE4 in Alzheimer’s disease and potential therapeutic targets
Zhang, L., Xia, Y., & Gui, Y. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1199434 · Cited by 41
Neuroimmunometabolism: A New Pathological Nexus Underlying Neurodegenerative Disorders
Mitra, S., Banik, A., Saurabh, S., Maulik, M., & Khatri, S. (2022) · Journal of Neuroscience · doi:10.1523/jneurosci.0998-21.2022 · Cited by 45
“Surprisingly, TREM2 haploinsufficiency increases tau pathology and inflammatory responses more than complete knockdown of TREM2 in a mouse model of tauopathy, suggesting a dynamic role of TREM2 in regulating neuroinflammation by a probable compensatory mechanism in microglia ( Sayed et al., 2018).”
The role of TREM2 in Alzheimer's disease; evidence from transgenic mouse models
Karanfilian, L., Tosto, M. G., & Malki, K. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.09.004 · Cited by 40
Glial cells and adaptive immunity in frontotemporal dementia with tau pathology
Hartnell, I. J., Blum, D. L., Nicoll, J. A. R., Dorothée, G., & Boche, D. (2020) · Brain · doi:10.1093/brain/awaa457 · Cited by 41
The Emerging Roles and Therapeutic Potential of Soluble TREM2 in Alzheimer’s Disease
Zhong, L., & Chen, X. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00328 · Cited by 40
“Other studies have evaluated the impacts of Trem2 deficiency, TREM2 mutation, or human TREM2 expression in amyloid or tau mouse models (Ulrich et al., 2014; Jay et al., 2015; Wang et al., 2015; Bemiller et al., 2017; Leyns et al., 2017, 2019; Cheng-Hathaway et al., 2018; Lee et al., 2018; Sayed et al., 2018; Song et a…”
BackgroundCarrier, M., Šimončičová, E., St‐Pierre, M., McKee, C., & Tremblay, M. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.749737 · Cited by 37
Reduction of the RNA Binding Protein TIA1 Exacerbates Neuroinflammation in Tauopathy
LeBlang, C. J., Medalla, M., Nicoletti, N. W., Hays, E. C., Zhao, J., Shattuck, J. E., Cruz, A. L., Wolozin, B. L., & Luebke, J. I. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00285 · Cited by 38
“…occurs in the hippocampus of P301S transgenic mice, with microglial reactivity beginning as early as 4 months of age, and increasing in severity with disease progression (Yoshiyama et al., 2007; López-González et al., 2015; Schweig et al., 2017; Dejanovic et al., 2018; Sayed et al., 2018).”
Denver, P., D’Adamo, H., Hu, S., Zuo, X., Zhu, C., Okuma, C., Kim, P., Castro, D., Jones, M. R., Leal, C. D. R., et al. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01269 · Cited by 37
“Introduction of human tau or frontotemporal tau dementia mutations can lead to development of neurofibrillary tangles, but those models do not precisely recapitulate pathogenesis in AD, in part because AD patients do not have tau mutations driving tauopathy (Sydow et al., 2011; Sayed et al., 2018).”
BackgroundMicroglial TREM2 at the Intersection of Brain Aging and Alzheimer’s Disease
Qu, W., & Li, L. (2021) · The Neuroscientist · doi:10.1177/10738584211040786 · Cited by 38
Etxeberria, A., Shen, Y.-A. A., Vito, S., Silverman, S. M., Imperio, J., Lalehzadeh, G., Soung, A. L., Du, C., Xie, L., Choy, M. K., et al. (2024) · The Journal of Neuroscience · doi:10.1523/jneurosci.2347-23.2024 · Cited by 34
Konishi, H., & Kiyama, H. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104878 · Cited by 33
TREM2 and Microglia Contribute to the Synaptic Plasticity: from Physiology to Pathology
Yu, C.-J., Wang, M., Ruiyang, L., Wei, T., Yang, H.-C., Yin, Y., Mi, Y., Qin, Q., & Tang, Y. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03100-1 · Cited by 34
TREM2 in Alzheimer's disease: Structure, function, therapeutic prospects, and activation challenges
Zgórzyńska, E. (2024) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2024.103917 · Cited by 29
Ghimire, A., Rehman, S. A., Subhani, A., Khan, M. A., Rahman, Z., Iqubal, M. K., & Iqubal, A. (2025) · hLife · doi:10.1016/j.hlife.2024.11.006 · Cited by 32
“TREM-2, the triggering receptor 2 on myeloid cells, whose soluble form is cerebrospinal fl uid (CSF) soluble TREM-2, is positively correlated with CSF PGRN [78].”
Roles of TREM2 in Alzheimer’s disease
Qi, X., Zhu, K., Ke, W., Wang, J., Mao, S., & Chen, G. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00515-3 · Cited by 38
“Conversely, while complete KO results in microglial dysfunction, the complete absence of TREM2 may trigger compensatory mechanisms that mitigate inflammatory responses [361, 365].”
InfluentialVautheny, A., Duwat, C., Aurégan, G., Joséphine, C., Hérard, A.-S., Jan, C., Mitja, J., Gipchtein, P., Gaillard, M.-C., Buée, L., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105398 · Cited by 28
Asparagine endopeptidase cleaves tau at N167 after uptake into microglia
Behrendt, A., Bichmann, M., Ercan-Herbst, E., Haberkant, P., Schöndorf, D. C., Wolf, M., Fahim, S. A., Murolo, E., & Ehrnhoefer, D. E. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104518 · Cited by 26
Chen, K., Li, F., Zhang, S., Chen, Y., Ikezu, T. C., Li, Z., Martens, Y. A., Qiao, W., Meneses, A. D., Zhu, Y., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03420-8 · Cited by 29
“Notably, two other studies found that complete deletion of the murine Trem2 gene does not significantly affect tau pathology in PS19 mice [26, 31].”
STING Deletion Protects Against Amyloid β‐induced Alzheimer's Disease Pathogenesis
Thanos, J. M., Campbell, O. C., Cowan, M. N., Bruch, K. R., Moore, K. A., Ennerfelt, H. E., Natale, N. R., Mangalmurti, A., Kerur, N., & Lukens, J. R. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.70305 · Cited by 26
“57 The divergent roles that many discrete and hippocampal synaptic loss.”
Differential Roles of TREM2+ Microglia in Anterograde and Retrograde Axonal Injury Models
Manich, G., Gómez‐López, A. R., Almolda, B., Villacampa, N., Recasens, M., Shrivastava, K., González, B., & Castellano, B. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.567404 · Cited by 27
“…being coincident with the previous general in vivo data in chronic (Jay et al., 2017a; Sayed et al., 2018) and acute CNS inflammatory injuries (Saber et al., 2017; Scott-Hewitt et al., 2017; Wu et al., 2017), as well as in other axonal injury models (Kobayashi et al., 2016; Tay et al., 2018).”
ResultKnowledge gaps in Alzheimer's disease immune biomarker research
Morgan, D., & Mielke, M. M. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12342 · Cited by 26
Anand, C., Maia, P. D., Torok, J., Mezias, C., & Raj, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-25131-3 · Cited by 27
Lin, C., Kong, Y., Chen, Q., Zeng, J., Pan, X., & Miao, J. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1420731 · Cited by 24
Microglia in Alzheimer’s Disease
Süß, P., & Schlachetzki, J. C. M. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200212155234 · Cited by 26
TREM2 Agonism with a Monoclonal Antibody Attenuates Tau Pathology and Neurodegeneration
Fassler, M., Benaim, C., & George, J. (2023) · Cells · doi:10.3390/cells12111549 · Cited by 22
“In a later study using the same murine model, heterozygous expression but not full deletion of TREM2 was associated with an accelerated Tau pathology [13].”
BackgroundZhao, Y., Guo, Q., Tian, J., Liu, W., & Wang, X. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102596 · Cited by 23
Pathways linking Alzheimer’s disease risk genes expressed highly in microglia
Hodges, A. K., Piers, T. M., Collier, D., Cousins, O., & Pocock, J. M. (2021) · Neuroimmunology and Neuroinflammation · doi:10.20517/2347-8659.2020.60 · Cited by 21
“In Tau-driven models, the picture is more complex with some studies showing loss of TREM2 to be protective in the presence of Tau pathology([124,125]) while others show it leads to worse outcomes([126,127]).”
APOEε4 and risk of Alzheimer’s disease – time to move forward
Lefterov, I. M., Fitz, N. F., Lü, Y., & Koldamova, R. P. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1195724 · Cited by 25
“In P301S tau mice expressing mouse Apoe the loss of Trem2 (Sayed et al., 2018; Leyns et al., 2019) or the expression of loss-of-function R47H variant (Gratuze et al.”
BackgroundCharacterization of gene expression profiles in the mouse brain after 35 days of spaceflight mission
Holley, J. M., Stanbouly, S., Pecaut, M. J., Willey, J. S., Delp, M. D., & Mao, X. W. (2022) · npj Microgravity · doi:10.1038/s41526-022-00217-4 · Cited by 22
The innate immune response in tauopathies
Johnson, A. M., & Lukens, J. R. (2023) · European Journal of Immunology · doi:10.1002/eji.202250266 · Cited by 22
Alzheimer’s Disease Genetics: A Dampened Microglial Response?
Chatila, Z. K., & Bradshaw, E. M. (2021) · The Neuroscientist · doi:10.1177/10738584211024531 · Cited by 20
TREM2-Deficient Microglia Attenuate Tau Spreading In Vivo
Lee-Gosselin, A., Jury-Garfe, N., You, Y., Dabin, L., Soni, D., Dutta, S., Rochet, J.-C., Kim, J., Oblak, A. L., & Lasagna-Reeves, C. A. (2023) · Cells · doi:10.3390/cells12121597 · Cited by 19
“total reduction enhanced tau phosphorylation and aggregation [18].”
BackgroundInfluentialCholesterol Metabolism in CNS Diseases: The Potential of SREBP2 and LXR as Therapeutic Targets
Wang, N.-Q., Sun, P.-X., Shen, Q.-Q., & Deng, M.-Y. (2025) · Molecular Neurobiology · doi:10.1007/s12035-024-04672-w · Cited by 19
“Notably, studies have shown that TREM2 haploinsufficiency causes more severe impairments in microglial function and exacerbates tau pathology compared to complete TREM2 loss [114].”
Ayyubova, G. (2023) · European Journal of Neuroscience · doi:10.1111/ejn.15914 · Cited by 21
“Some studies showed that loss of TREM2 is protective in the presence of tau pathology (Leyns et al., 2019), whereas others indicate that it is detrimental (Bemiller et al., 2017; Sayed et al., 2018).”
BackgroundMicroglia Biomarkers in Alzheimer’s Disease
Zhang, P., Hu, H., Tan, L., & Yu, J. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02348-3 · Cited by 19
Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways
Ibanez, K. R., McFarland, K. N., Phillips, J., Allen, M., Lessard, C. B., Zobel, L., De La Cruz, E. G., Shah, S., Vo, Q., Wang, X., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01044-1 · Cited by 18
Sánchez‐Ruiz de Gordoa, J., Erro, M. E., Vicuña‐Urriza, J., Zelaya, M. V., Tellechea, P., Acha, B., Zueco, S., Urdánoz‐Casado, A., Roldán, M., Blanco‐Luquin, I., et al. (2020) · Movement Disorders · doi:10.1002/mds.27992 · Cited by 18
“Intriguingly, TREM2 haploinsufficiency, but not complete loss of TREM2, exacerbates tau pathology and impairs microglia response to injury in the transgenic PS19Tg mouse model primary tauopathy.(31) We show that TREM2 expression levels are augmented in a brain area affected by pathological p-tau deposits.”
BackgroundImmunological aspects of central neurodegeneration
Niso‐Santano, M., Fuentes, J. M., & Galluzzi, L. (2024) · Cell Discovery · doi:10.1038/s41421-024-00666-z · Cited by 17
“To add yet another layer of complexity, in at least some AD models, while Trem2 haploinsuf fi ciency appears to aggravate tau pathology in mice, complete Trem2 loss reportedly limits tau-driven microglial activation and atrophy 48 .”
Metadata
- Authors
- Sayed, F. A., Telpoukhovskaia, M., Kodama, L., Li, Y., Zhou, Y., Le, D., Hauduc, A., Ludwig, C., Gao, F., Clelland, C., Zhan, L., Cooper, Y. A., Davalos, D., Akassoglou, K., Coppola, G., & Gan, L.
- Affiliations
- Gladstone Institutes (US)
- University of California, Los Angeles (US)
- Corresponding author
- Gan, Li
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2018-09-19
- Volume
- 115
- Issue
- 40
- Pages
- 10172-10177
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC6176614
- OpenAlex
- W2890556232
- Cited by
- 229
- References
- 35
- Citations by year
- 2026: 15 · 2025: 23 · 2024: 31 · 2023: 40 · 2022: 44 · 2021: 33 · 2020: 19 · 2019: 21 · 2018: 3
- FWCI
- 8.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
- Funders
- HHS | NIH | National Institute on Aging (R01AG051390, R01AG054214)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Keywords
- TREM2, Alzheimer's disease, tauopathy, microglial activation, TREM2 knockout mice, pro-inflammatory markers
- MeSH terms
- Aging, Alzheimer Disease, Animals, Membrane Glycoproteins, Receptors, Immunologic, Microglia, Mice, Knockout, Mutation, Missense, Mice, Haploinsufficiency, Hemizygote
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review